O
bstructive sleep apnea (OSA) is independently associated with increased cardiovascular morbidity and mortality. Multiple pathways by which OSA may promote cardiovascular disease have been reported, but ability to reverse these pathways is not fully established.
Kasai and colleagues 1 now provide additional evidence that treatment with continuous positive airway pressure (CPAP) affects arterial stiffness (evaluated by cardio-ankle vascular index) and markers of inflammation. Comparing patients with OSA to age-and body mass index-matched control subjects revealed that moderate to severe patients with OSA had higher values of cardio-ankle vascular index than controls. Moreover, consistent with some previous studies, cardio-ankle vascular index decreased after 1 month of CPAP therapy without significant changes in blood pressure and heart rate. 2, 3 Despite the significant results in the arterial stiffness, the most intriguing data were derived from the two inflammatory markers used in this study. First of all, pentraxin-3 levels in the moderate to severe OSA group were significantly higher than those in the control and mild OSA groups. C-reactive protein levels were also elevated in the moderate to severe group in comparison to patients with mild OSA, but interestingly, not different from the control group. The reasons for the latter results are not clear but may relate to sample size. Second, pentraxin-3, but not C-reactive protein was independently associated with cardio-ankle vascular index. Finally, 1 month of effective CPAP treatment significantly decreased pentraxin-3 but not C-reactive protein. Altogether, these provocative results raise the following questions: (i) is pentraxin-3 more sensitive than C-reactive protein to detect low grade inflammation associated with vascular damage in OSA? (ii) How long does it take for OSA to induce inflammation or for treatment to reverse inflammation? Both C-reactive protein and pentraxin-3 are pentraxins, a family of evolutionarily conserved pattern-recognition proteins that are made up of five identical subunits. Unlike C-reactive protein (short pentraxin), which is produced primarily by hepatocytes and is nonspecific marker of inflammation, pentraxin-3 (long pentraxin) is synthesized by cells directly involved in atherosclerosis including vascular endothelial cells, smooth muscle cells, and macrophages. Therefore, it is conceivable that pentraxin-3 may provide more explicit information on development and progression of vascular damage than C-reactive protein. Supporting this statement, Peri et al. analyzed blood samples from patients with symptoms of acute myocardial infarction. 4 They found that pentraxin-3 peaked at 7.5 h after coronary care unit admission returning to the normal in all but three patients at hospital discharge. Plasma C-reactive protein peaked 24 h after coronary care unit admission and remained elevated at discharge in most patients (73%).
In the OSA scenario, it is not clear how long does it take to patients with OSA present significant increase in markers of inflammation. The challenge to show this is not only a matter of marker but also a matter of characterizing when OSA per se begins, since diagnosis is usually years after symptoms begin. The effect of on inflammatory markers is also debatable. As Kasai reported, 1 1 month of CPAP therapy had no effect on C-reactive protein in a randomized controlled study. 5 However, at least one study showed a significant reduction of C-reactive protein after >3 months of CPAP. 2 How to explain these differences? Kasai and colleagues have shed light on this important issue. Beyond differences in study designs, it is conceivable that the development of new markers really reflects how fast treatment with CPAP attenuates the systemic inflammation in patients with OSA.
Disclosure: The author declared no conflict of interest.
